The review looked at more than three dozen studies and found no evidence that acetaminophen increased the risk of neurodevelopmental disorders in children.

Roche Holding shares rose 2.1% Wednesday after the Swiss drugmaker reported positive results from a new study of an experimental breast cancer drug. The pill, giredestrant, reduced the risk of death ...

A promising drug combination could help people with leukemia who don't respond to traditional treatments, according to new research. A team at Oregon Health and Science University made the discovery ...

Reviva Pharmaceuticals Holdings Inc. (NASDAQ: RVPH) on Tuesday announced a regulatory update following a pre-New Drug Application (pre-NDA) meeting with the U.S. Food and Drug Administration (FDA).

The drug targets a specific mutation that applies to only 2% of ALS patients. A new drug may slow progression of -- and even reverse -- symptoms of a rare form of amyotrophic lateral sclerosis, or ALS ...

(The Hill) — Medicare enrollees could save roughly half of what they usually pay for certain drugs next year, according to a study from the AARP. The study, published Thursday, found that the ...

A cancer-drug combination from Merck, Pfizer and Astellas Pharma has hit its goal in a second late-stage study in patients with a hard-to-treat form of bladder cancer. The companies on Wednesday said ...

CLEVELAND — The Food and Drug Administration has approved expanded use of Addyi, a medication designed to address low sexual desire in women, now including post-menopausal women under age 65. Sprout ...

A new survey from SiriusXM Media details the issues that many people have with the current state of TV drug ads—and highlights an opportunity for greater investment in audio ads instead. The pharma- ...

Despite previous excitement around a potential link between GLP-1 drugs and a reduced risk of cancer, new research suggests the popular medications “probably have little or no effect” on a person’s ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...